The patients with fluroquinolone exposure who were also using statins, aromatase inhibitors, or glucocorticoids (adjusted HR: 1.91, 1.43, 1.51, respectively, p < 0.001) had a higher risk of tendon disorders, compared to those without exposure to those medications. Here, CYP19A1 is linked to disease of the tendon.